Navigation Links
Novel target found for chemotherapy-resistant leukemia cells
Date:5/12/2014

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

Nora Heisterkamp, PhD, and colleagues at The Saban Research Institute of Children's Hospital Los Angeles have discovered that by targeting the B-cell activating receptor (BAFF-R), chemotherapy-resistant precursor B acute lymphoblastic leukemia cells (pre-B ALL) can be selectively killed in vivo and in vitro. Results will be published on May 13 in Molecular Cancer Therapeutics.

Acute lymphoblastic leukemia (ALL) is characterized by an excessive amount of white blood cell precursors, called B-cell lymphoblasts, in the blood and bone marrow. B-cell lineage ALL (pre-B ALL) accounts for 80 to 85% of childhood ALL. Although the cure rate has increased, further advances can only be achieved by identifying mechanisms to treat specific subsets of chemotherapy-resistant leukemia cells.

In a previous study (Leukemia, 2013), the researchers had shown that BAFF-R is expressed on pre-B ALL cells but not on their normal counterparts, making selective killing of ALL cells possible by targeting this receptor.

"We've now demonstrated that BAFF-R is a strong potential therapeutic target for treating chemotherapy-resistant leukemia cells, without damaging healthy cells," said Heisterkamp, who is also professor of Research, Pediatrics and Pathology at the Keck School of Medicine of the University of Southern California.

Using a genetically-engineered antibody (anti-BAFF-R monoclonal antibody), Heisterkamp and colleagues have demonstrated that the BAFF-R could be successfully blocked in a dose-dependent manner. Inhibition of BAFF-R function rendered leukemia cells less viable in mouse models of the disease. Also, the presence of this antibody on the pre-B ALL cells resulted in increased killing of the cancer cells by natural killer (NK) cells and macrophages.

"We found that human pre-B ALL cells could be even further reduced when the anti-BAFF-R antibody was combined with chemotherapy or another therapeutic agent," said Heisterkamp. "We are looking at a potential one, two punch." Heisterkamp and her colleagues will continue to evaluate the use of this antibody for the treatment of ALL.


'/>"/>

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles
Source:Eurekalert  

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
10. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
11. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel target found for chemotherapy-resistant leukemia cells
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to ... Multi-Cook Oven offers up to four ovens in one. Control temperature, fan speed ... unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this ...
(Date:2/22/2017)... FRANCISCO BAY AREA - NORTHERN CALIFORNIA (PRWEB) , ... ... ... (PMF) aims to expand the pipeline and the number of African American/Black ... that encourages medical students and residents to pursue their careers as physicians in ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton ... Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon cutting ... employees, the construction team and tribal leadership. , Choctaw Nation Durant Regional ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... announce that Marc Philpart, senior director at PolicyLink, will be the keynote speaker ... about the Boys and Men of Color Framework, which develops comprehensive strategies to ...
(Date:2/21/2017)... ... 21, 2017 , ... As recently as 2015, rhinoplasty was one of the ... Plastic Surgeons. Some patients want to make a change in the appearance of their ... breathing ability. The team at usrhinoplasty.org is expanding its article database to ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 2017 Micro Guide Catheters Market: Overview ... Micro Guide Catheters are used ... clinics and ambulatory surgery centers etc. Micro guide ... selection of micro guide catheter depends on the ... body. Micro guide catheters are available in different ...
(Date:2/21/2017)... , Feb. 21, 2017  Luminex Corporation (NASDAQ: ... of directors has authorized the initiation of a quarterly cash ... This initial cash dividend will be payable on April 14, ... business on March 24, 2017. The board ... quarterly cash dividend of $0.06 to holders of its common ...
(Date:2/21/2017)...  /PR Newswire/ -- UBM Medica,s Eye Care Group ... of Modern Retina ( www.modernretina.com ), a ... Built upon the success of Ophthalmology Times ... innovations in the areas of retinal surgery, clinical information, ... current informational needs and filling existing educational gaps, ...
Breaking Medicine Technology: